5,182 Pacira BioSciences (PCRX) shares withheld to cover CCO taxes

Rhea-AI Filing Summary

Pacira BioSciences, Inc. reported a routine insider tax-withholding transaction by its Chief Commercial Officer, Brendan Teehan. On 01/30/2026, 5,182 shares of common stock were withheld by the company at $20.54 per share to cover tax obligations upon vesting of a restricted stock unit award. After this withholding, Teehan directly beneficially owned 49,220.268 shares of Pacira common stock.

Insider Trade Summary

Net Seller: 5,182 shares

Net Sell 1 txn

Insider Teehan Brendan

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	5,182	$20.54	$106K

Holdings After Transaction: Common Stock — 49,220.268 shares (Direct)

Footnotes (1)

1. F1. Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.

FAQ

What insider transaction did Pacira BioSciences (PCRX) disclose in this Form 4?

Pacira disclosed a routine tax-withholding transaction. On 01/30/2026, 5,182 shares of common stock were withheld by the issuer at $20.54 per share to satisfy Brendan Teehan’s tax obligations from a vested restricted stock unit award.

Who is the insider involved in this Pacira BioSciences (PCRX) Form 4 filing?

The insider is Brendan Teehan, Pacira’s Chief Commercial Officer. He is an officer of Pacira BioSciences, Inc. and reported this single transaction involving company common stock and related tax withholding on 01/30/2026.

How many Pacira (PCRX) shares were withheld and at what price in this filing?

A total of 5,182 Pacira common shares were withheld at $20.54 each. These shares were retained by the issuer specifically to cover tax withholding obligations tied to the vesting of a restricted stock unit award.

Was the Pacira (PCRX) insider transaction an open-market sale by Brendan Teehan?

No, it was not an open-market sale. The Form 4 notes transaction code “F” and explains the 5,182 shares represent stock withheld by Pacira to cover tax withholding obligations from a restricted stock unit vesting event.

How many Pacira BioSciences (PCRX) shares does Brendan Teehan own after this transaction?

Following the transaction, Brendan Teehan beneficially owned 49,220.268 shares. The Form 4 states this remaining position is held directly after 5,182 shares were withheld to satisfy associated tax obligations.

What does transaction code "F" indicate in the Pacira (PCRX) Form 4?

Transaction code “F” indicates shares withheld to pay taxes. In this case, Pacira withheld 5,182 shares of common stock from Brendan Teehan when a restricted stock unit award vested, covering required tax withholding obligations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/03/2026 - 06:23 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Teehan Brendan

(Last) (First) (Middle)

C/O PACIRA BIOSCIENCES, INC.

2000 SIERRA POINT PARKWAY, SUITE 900

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/30/2026		F		5,182(1)	D	$20.54	49,220.268	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.

Remarks:

	/s/ Kristen Williams, Attorney-in-Fact	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.